NCT00192270已完成2 期
A Prospective, Open-label, Phase II, Multi-center Study of the Safety, Tolerability and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children, Aged 6 to 17 Years
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 498
- 试验地点
- 6
- 主要终点
- The number of subjects achieving strain-specific hemagglutination inhibition (HAI) antibody seroconversion post Dose 1
研究概览
简要总结
The study was designed to determine the number of doses of CAIV-T required to effectively immunize children and adolescents in the 6 to 17 year age group.
详细描述
This was a phase II, prospective, open-label, multicenter, outpatient study designed to evaluate the safety, tolerability, and immunogenicity of one or two doses of CAIV-T in children and adolescents between 6 and 17 years of age. Subjects were allocated to one of three study groups according to age at the time of enrollment: study group one consisted of subjects between 6 and 9 years of age, group two of subjects 10 to 12 years of age, and group three of subjects 13 to 17 years of age.
Approximately 450 subjects (ie, 150 subjects per age group) participated in the study and were scheduled to receive two intranasal doses of CAIV-T separated by 35 ± 7 days in an open-label manner.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •who are at least 6 years and not more than 17 years of age at the time of enrollment;
- •who, if female and is post-menarche, has provided a negative pregnancy test; · who are in good health as determined by medical history, physical examination and clinical judgement;
- •who have provided written informed consent (as appropriate and according to national guidelines) and whose parent(s) or legal guardian(s) have provided written informed consent after the nature of the study has been explained; 13 who, along with their parent(s) or legal guardian(s), will be available for duration of the study (approximately three months);
- •who, together with their parent(s) or legal guardian(s), can be reached by study staff for the post-vaccination contacts [telephone, clinic visit or home visit].
排除标准
- •who are perceived to be unavailable or difficult to contact for evaluation or study visits during the study period and whose parent(s) or legal guardian(s) are perceived to be unreliable or difficult to contact for evaluation or study visits during the study period;
- •with any serious chronic disease (e.g., with signs of cardiac or renal failure or severe malnutrition), including progressive neurological disease;
- •with Down's syndrome or other known cytogenetic disorders;
- •with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids;
- •who received any blood products, including immunoglobulin, in the period from six months prior to vaccination through to the conclusion of the study;
- •for whom there is intent to administer any other investigational vaccine or agent from one month prior to enrollment through to the conclusion of the study;
- •have an immunosuppressed or immuno-compromised individual living in the same household;
- •who, at any time prior to entry into this study, received a dose of any influenza vaccine (commercial or investigational)
- •who, in the two weeks prior to entry into this study, received a dose of any influenza treatment (commercial or investigational)
- •with a documented history of hypersensitivity to egg or egg protein or any other component of the study vaccine;
- •with a clinically confirmed respiratory illness with wheezing within two weeks prior to enrollment;
- •who received aspirin (acetylsalicylic acid) or aspirin-containing products in the two weeks prior to enrollment or for which use is anticipated during the study;
- •who were administered any live virus vaccine within one month prior to enrollment or expect receipt of another live virus vaccine within one month of vaccination in this study;
- •with any medical conditions that in the opinion of the investigator might interfere with interpretation of the study results; If any of these criteria are met following enrolment, the subject will be excluded from subsequent vaccine dosing.
- •Note: A pregnant household member is not considered a contraindication to enrollment.
结局指标
主要结局
The number of subjects achieving strain-specific hemagglutination inhibition (HAI) antibody seroconversion post Dose 1
时间窗: Day 0, Day 35 post Dose 1
Immunogenicity was evaluated by comparison of pre and post-vaccination strain-specific titers of serum HAI antibody. Seroconversion was defined as a four-fold or greater rise in serum HAI antibody titer.
次要结局
- The number of subjects achieving strain-specific HAI antibody seroconversion post Dose 1(Day 0, Day 35 post Dose 2)
- The number of subjects reporting any reactogenicity event post dose(Days 0-10)
- The number of subjects reporting any adverse event post dose(Days 0-10)
- The number of subjects reporting serious adverse events post dose(Days 0-42)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
3 期
Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or OlderPoliomyelitisTetanusDiphtheriaPertussisNCT01287949Sanofi Pasteur, a Sanofi Company342
已完成
3 期
Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying TherapyMultiple Sclerosis, Relapsing-RemittingMultiple SclerosisNCT05028634Celgene63
已完成
1 期
Phase I/IIa Dose-escalation Clinical Study of VAC-3SHIV-1 InfectionNCT01549119InnaVirVax33
进行中（未招募）
2 期
Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and AboveHerpes ZosterNCT05856084MAXVAX Biotechnology Limited Liability Company924
已完成
3 期
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingNCT02545868Hoffmann-La Roche102